Aceto has completed the divestment of its Rising Pharmaceuticals generics unit, is moving ahead with the disposal of its chemicals business and has disclosed a bonus incentive scheme for its CEO, William Kennally, aimed at securing the maximum value for its assets as part of bankruptcy proceedings.
Aceto has completed the sale of its Rising Pharmaceuticals generics business – along with Rising’s subsidiaries and related assets – to Shore Suven Pharma for $15m.
At the same time, the company has firmed up plans to sell its chemicals business to an affiliate of New...